Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03818750
Other study ID # 35RC18_8845_IMAJ
Secondary ID 2018-A00219-46
Status Completed
Phase N/A
First received
Last updated
Start date June 13, 2018
Est. completion date March 7, 2019

Study information

Verified date March 2019
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Impact of marketing of alcohol products on young people


Description:

Responsible for 3.3 million deaths worldwide, alcohol consumption causes diseases (liver cirrhosis, cancers, etc.) and social problems (injuries, road accidents, alcohol dependence, etc.). With one of the highest consumption rate in Europe, alcohol is the second cause of avoidable mortality in France after tobacco (49.000 alcohol attributable deaths in 2009) and its social cost is estimated to 120 billion euros. French teenage population is particularly associated with heavy drinking patterns: in 2014, 49% of 17-year olds declared heavy episodic drinking.

In that regard, several measures are recommended by health actors to combat this issue: minimum unit pricing, sales ban to minor, low blood alcohol concentration for drivers, etc. A specific measure concerns alcohol advertising restrictions. Some countries implemented alcohol advertising regulation laws (Poland, Sweden, Finland, Estonia, etc.), including France with the Evin law passed in 1991. This French law mandates advertising (and packaging) content to strictly convey factual information and objective qualities of alcohol products and thus bans attractive ads based on image and lifestyle evocations (seduction, power, etc.).

The objective of this research is to investigate whether statutory framework for alcohol advertising (e.g., Evin law) can effectively protect people against misleading, suggestive, and appealing content. Little research has been conducted on this topic in spite of WHO's recommendations (most research has explored the influence of exposure to ads but not the impact of content).


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date March 7, 2019
Est. primary completion date March 7, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria:

- volunteer males

- aged 18-25

- right-handed

- persons that consume alcohol : " light drinkers " or "heavy drinkers" (defined with the AUDIT scale, scores between 1 to 7)

- written consent and agreement consent will be given

- Affiliated to the French social insurance

Exclusion Criteria:

- color-blind persons

- misuse of psychoactive products (except tobacco) (cannabis : no regular consumers -more than 10 times per month ; no users of other illicit drugs - even for occasional consumption)

- non fluent french speaking persons (people who couldn't understand instructions or asked questions)

- persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty

Related to the MRI:

- Cardiac pacemaker or implanted defibrillator

- Cochlear implant

- Peripheral or neuronal stimulator

- Intra-ocular or brain metallic foreign bodies

- Any other contraindications to MRI

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MRI
Subjects review alcohol ads in different contexts (neutral context vs positive context such as parties and sport) and answer with buttons lever while being in the MRI to express their desire to consume alcohol or not. Subjects will be exposed to 288 ads set up.
Behavioral:
Alcohol Use Disorders Identification Test
Questionnaire

Locations

Country Name City State
France CHU de Rennes Rennes

Sponsors (2)

Lead Sponsor Collaborator
Rennes University Hospital Ecole des Hautes Etudes en Santé Publique (EHESP)

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in brain activation in areas involved in the control of reward and motivation when looking at neutral versus contextual ads Significant change in cerebral activity (expressed as a significant variation in hemodynamic response BOLD) in the condition of alcohol ads with versus without context (party, sport, people) in areas involved in the control of reward and motivation (striatum dorsal, insula) Month 1
See also
  Status Clinical Trial Phase
Recruiting NCT05054738 - CRP and S&A for Inpatient Veterans N/A
Completed NCT02233738 - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services N/A
Completed NCT05877807 - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT00536146 - The Stress-Hormone System in Alcohol-Dependent Subjects N/A
Terminated NCT00890149 - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults Phase 2
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT01553136 - Varenicline Treatment of Alcohol Dependence in Smokers Phase 2
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01389297 - Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery N/A
Completed NCT01760785 - Valproate for Mood Swings and Alcohol Use Following Head Injury N/A
Completed NCT00768508 - Combined Pharmacotherapies for Alcoholism Phase 3
Completed NCT01113164 - Matching Genotypes and Serotonergic Medications for Alcoholism Phase 1
Completed NCT00127231 - Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women N/A
Terminated NCT02842528 - Cognitive Vulnerability Factors in Alcohol-dependence N/A
Completed NCT00367575 - An Internet-based Intervention for Problem Drinking N/A
Completed NCT00223639 - New Medications to Treat Alcohol Dependence Phase 2
Completed NCT00583440 - 12-step Facilitation for the Dually Diagnosed Phase 1/Phase 2
Completed NCT00167687 - Prazosin Alcohol Dependence IVR Study Phase 4